AT278 – Ultra-Concentrated Rapid Acting Insulin

AT278 is a concentrated novel formulation of rapid acting insulin that has been designed to accelerate the absorption of insulin post injection. AT278 has the potential to provide the clinical benefits of a rapid acting insulin to patients who have high daily insulin requirements (>200 units/day) via a single injection and enable the use of next generation miniaturised insulin pump delivery devices. AT278 with an improved profile to significantly improve clinical outcomes and patient convenience by reducing the number of injections and enabling Type 2 diabetic patients with high insulin usage to access pumps.

AT278 has the potential to be the first concentrated rapid acting insulin available for patients.

 

What is Diabetes?

What is hypoglycaemia and hyperglycemia?

The Medical Need

There is a high unmet need for a stable, rapid-acting, ultra-concentrated insulin of up to 1000 U/mL, that can offer a vastly superior mealtime insulin product for those people with diabetes requiring >200 U/day.

An ultra-concentrated product is key for the miniaturisation of insulin delivery devices. Next-generation device technology such as wearable, continuous administration patch pumps and implants, are critical future developments for people living with diabetes. In particular, these devices will help to improve compliance in difficult to treat groups such as children and teenagers. Such deliver systems when combined with a rapid acting insulin improve glycaemic control and compliance, thereby reducing adverse events, as well as overall complications and morbidity.

As yet, there are no concentrated (>200U/mL) rapid acting insulin products on the market.

The Market

Diabetes is a large and growing market:

  • Currently there are ~ 463m people with diabetes, with ~26m insulin users and a $22bn global insulin market¹
  • By 2040 there will be an estimated 700m diabetics¹

Whilst there are rapid acting insulins available on the market, there remains a significant need for faster acting insulins as diabetes care advances towards more personalised treatment regimes and sophisticated drug/device combinations such as the automated Artificial Pancreas system.

Next generation delivery products will increasingly be miniaturised and require both concentrated and faster-acting insulin:

  • Reduces the number of injections required each day for high dose patients
  • Patch pumps and smaller devices significantly improve patient adherence, particularly for children and teenagers
  • Automated artificial pancreas is the holy grail removing the burden of self-management altogether

¹International Diabetes Federation, Diabetes Atlas, 2019